Zogenix

ZGNX NASDAQ
39.02
+1.23
+3.25%
After Hours: 39.02 0 0.00% 16:51 05/22 EDT
Open
37.85
Prev Close
37.79
High
39.04
Low
37.37
Volume
811.71K
Avg Vol (3M)
771.44K
52 Week High
62.75
52 Week Low
33.43
% Turnover
1.91%
Market Cap
1.66B
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Company Profile

Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. ZX008 has received orphan drug designation in the United States and European Union (EU), for the treatment of Dravet syndrome. The Company has an additional product candidate, Relday (risperidone once-monthly long-acting injectable) for the treatment of schizophrenia. Relday is a long-acting injectable formulation of risperidone. Risperidone is used to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. It has completed the Phase I program for Relday.
MORE >

Recently

Name
Price
%Change